<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03895554</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00000188</org_study_id>
    <nct_id>NCT03895554</nct_id>
  </id_info>
  <brief_title>Quantification of Myocardial Blood Flow by Positron Emission Tomography in Healthy Volunteers</brief_title>
  <acronym>PET Normals</acronym>
  <official_title>Quantification of Myocardial Blood Flow by Positron Emission Tomography in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ochsner Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ochsner Health System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To establish quantitative values of myocardial blood flow (MBF) in normal, healthy volunteers
      .
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We seek to establish quantitative values of myocardial blood flow in 20 normal, healthy
      volunteers using our existing 2D PET camera (Positron Attrius) and invasively validated
      software package (HeartSee) in order to 1) establish institutional values for which clinical
      patients can be compared to and 2) add to the collective data of the scientific community.
      Values to be measured will be resting myocardial blood flow (MBF), stress MBF and coronary
      flow reserve.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute myocardial blood flow at rest and stress in cc/min/g</measure>
    <time_frame>measured at the time of the cardiac PET stress scan</time_frame>
    <description>resting and stress MBF are in units of cc/min/g</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Normal Healthy Volunteers Without Chronic Medical Conditions</condition>
  <arm_group>
    <arm_group_label>Normal volunteers</arm_group_label>
    <description>Normal, healthy volunteers with undergo cardiac PET stress testing.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>cardiac PET stress test</intervention_name>
    <description>Volunteers will undergo cardiac PET stress testing</description>
    <arm_group_label>Normal volunteers</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Volunteers will be selected from the local community.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults ≥18 and &lt;40 years old

          -  Participants must be able to give informed consent.

          -  Ability to abstain from caffeine for 48 hours

        Exclusion Criteria:

          -  Any chronic cardiac disease or condition (e.g. hypertension, hyperlipidemia)

          -  Any chronic systemic disease or condition (e.g. diabetes, systemic lupus, rheumatoid
             arthritis)

          -  Tobacco use

          -  Family history in a first degree relative with clinical coronary artery disease
             (history of myocardial infarctio, percutaneous intervention or coronary artery bypass
             grafting) in men &lt;55 years old or women &lt;65 years old

          -  Severe claustrophobia

          -  Positive urine pregnancy test

          -  Inability to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Robert M Bober, MD</last_name>
    <phone>5048426821</phone>
    <email>rbober@ochsner.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hunter McDaniel</last_name>
    <phone>5047033272</phone>
    <email>hunter.mcdaniel@ochsner.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ochsner</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70120</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Robert Bober, MD</last_name>
      <phone>504-842-6821</phone>
      <email>rbober@ochsner.org</email>
    </contact>
    <contact_backup>
      <last_name>Hunter McDaniel</last_name>
      <phone>504.703.3272</phone>
      <email>hunter.mcdaniel@ochsner.org</email>
    </contact_backup>
    <investigator>
      <last_name>Robert Bober, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nichole Polin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Merrill Stewart, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joseph Englert, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Araujo LI, Lammertsma AA, Rhodes CG, McFalls EO, Iida H, Rechavia E, Galassi A, De Silva R, Jones T, Maseri A. Noninvasive quantification of regional myocardial blood flow in coronary artery disease with oxygen-15-labeled carbon dioxide inhalation and positron emission tomography. Circulation. 1991 Mar;83(3):875-85.</citation>
    <PMID>1900224</PMID>
  </reference>
  <reference>
    <citation>Bergmann SR, Herrero P, Markham J, Weinheimer CJ, Walsh MN. Noninvasive quantitation of myocardial blood flow in human subjects with oxygen-15-labeled water and positron emission tomography. J Am Coll Cardiol. 1989 Sep;14(3):639-52.</citation>
    <PMID>2788669</PMID>
  </reference>
  <reference>
    <citation>Sdringola S, Johnson NP, Kirkeeide RL, Cid E, Gould KL. Impact of unexpected factors on quantitative myocardial perfusion and coronary flow reserve in young, asymptomatic volunteers. JACC Cardiovasc Imaging. 2011 Apr;4(4):402-12. doi: 10.1016/j.jcmg.2011.02.008.</citation>
    <PMID>21492816</PMID>
  </reference>
  <reference>
    <citation>Renaud JM, DaSilva JN, Beanlands RS, DeKemp RA. Characterizing the normal range of myocardial blood flow with ⁸²rubidium and ¹³N-ammonia PET imaging. J Nucl Cardiol. 2013 Aug;20(4):578-91. doi: 10.1007/s12350-013-9721-3. Epub 2013 May 9. Erratum in: J Nucl Cardiol. 2013 Aug;20(4):702.</citation>
    <PMID>23657833</PMID>
  </reference>
  <reference>
    <citation>Merlet P, Mazoyer B, Hittinger L, Valette H, Saal JP, Bendriem B, Crozatier B, Castaigne A, Syrota A, Randé JL. Assessment of coronary reserve in man: comparison between positron emission tomography with oxygen-15-labeled water and intracoronary Doppler technique. J Nucl Med. 1993 Nov;34(11):1899-904.</citation>
    <PMID>8229231</PMID>
  </reference>
  <reference>
    <citation>Kern MJ, Bach RG, Mechem CJ, Caracciolo EA, Aguirre FV, Miller LW, Donohue TJ. Variations in normal coronary vasodilatory reserve stratified by artery, gender, heart transplantation and coronary artery disease. J Am Coll Cardiol. 1996 Nov 1;28(5):1154-60.</citation>
    <PMID>8890809</PMID>
  </reference>
  <reference>
    <citation>Renaud JM, Yip K, Guimond J, Trottier M, Pibarot P, Turcotte E, Maguire C, Lalonde L, Gulenchyn K, Farncombe T, Wisenberg G, Moody J, Lee B, Port SC, Turkington TG, Beanlands RS, deKemp RA. Characterization of 3-Dimensional PET Systems for Accurate Quantification of Myocardial Blood Flow. J Nucl Med. 2017 Jan;58(1):103-109. doi: 10.2967/jnumed.116.174565. Epub 2016 Aug 18.</citation>
    <PMID>27539843</PMID>
  </reference>
  <reference>
    <citation>Gould KL, Johnson NP, Bateman TM, Beanlands RS, Bengel FM, Bober R, Camici PG, Cerqueira MD, Chow BJW, Di Carli MF, Dorbala S, Gewirtz H, Gropler RJ, Kaufmann PA, Knaapen P, Knuuti J, Merhige ME, Rentrop KP, Ruddy TD, Schelbert HR, Schindler TH, Schwaiger M, Sdringola S, Vitarello J, Williams KA Sr, Gordon D, Dilsizian V, Narula J. Anatomic versus physiologic assessment of coronary artery disease. Role of coronary flow reserve, fractional flow reserve, and positron emission tomography imaging in revascularization decision-making. J Am Coll Cardiol. 2013 Oct 29;62(18):1639-1653. doi: 10.1016/j.jacc.2013.07.076. Epub 2013 Aug 28. Review.</citation>
    <PMID>23954338</PMID>
  </reference>
  <reference>
    <citation>Nesterov SV, Deshayes E, Sciagrà R, Settimo L, Declerck JM, Pan XB, Yoshinaga K, Katoh C, Slomka PJ, Germano G, Han C, Aalto V, Alessio AM, Ficaro EP, Lee BC, Nekolla SG, Gwet KL, deKemp RA, Klein R, Dickson J, Case JA, Bateman T, Prior JO, Knuuti JM. Quantification of myocardial blood flow in absolute terms using (82)Rb PET imaging: the RUBY-10 Study. JACC Cardiovasc Imaging. 2014 Nov;7(11):1119-1127. doi: 10.1016/j.jcmg.2014.08.003. Epub 2014 Oct 8.</citation>
    <PMID>25306543</PMID>
  </reference>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 27, 2019</study_first_submitted>
  <study_first_submitted_qc>March 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2019</study_first_posted>
  <last_update_submitted>March 27, 2019</last_update_submitted>
  <last_update_submitted_qc>March 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ochsner Health System</investigator_affiliation>
    <investigator_full_name>Robert Bober, M.D.</investigator_full_name>
    <investigator_title>Director of Cardiac Molecular Imaging</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Intention to publish the data in peer reviewed journal.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

